

RECEIVED

MAY 19 1993

GROUP 1800

1800

Group Art Unit: 1805 ✓ 180

Examiner: Schwadron, R.

FILE 10/13  
J. 8/10/93  
5-20-93

RECEIVED

MAY 19 1993

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: ANDERSON, DARRELL R., et al.

Serial No. 07/978,891

180

Filed: 13 November 1992

Title: THERAPEUTIC APPLICATION OF  
CHIMERIC ANTIBODY TO HUMAN B  
LYMPHOCYTE RESTRICTED  
DIFFERENTIATION ANTIGEN FOR  
TREATMENT OF B CELL  
LYMPHOMA

May 10, 1993  
La Jolla, CA

RESPONSE TO EXAMINER COMMUNICATION  
DATED APRIL 8, 1993

Hon. Commissioner of Patents and Trademarks  
BOX NON-FEE AMENDMENT  
Washington, D.C. 20231

RECEIVED

MAY 19 1993

GROUP 1800

Sir:

On April 19, 1993, the Office notified Applicants of a bona fide, but incomplete, response to the January 11, 1993 Notice to Comply. Applicants regret any inconvenience caused by the inadvertence.

The Office has noted certain errors in the submitted Sequence Listing, and has requested:

1. A substitute Computer Readable Form ("CRF") copy of the Sequence Listing;
2. A paper copy of the Sequence Listing with an amendment directing its entry into the Specification; and
3. A Rule 821 Statement.

Attached hereto please find: (1) a substitute CRF; a paper copy of the CRF; a Preliminary Amendment directing its entry into the Specification; and a Rule 821 Statement.

Applicants request that the foregoing be entered and that examination-on-the-merits for this case be initiated.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Richard P. Burgoon, Jr.", written in a cursive style.

Richard P. Burgoon, Jr.  
Intellectual Property Counsel  
Reg. No. 34,787  
IDEC Pharmaceuticals Corporation  
11099 N. Torrey Pines Road, #160  
La Jolla, CA 92037